ABSTRACT
Aortic endografts have become the preferred treatment for aneurysms of the descending thoracic aorta and the infrarenal aorta. The prevalence of endograft infections is about 0.6%, and with the growing number of patients with aortic endografts, the number of patients with endograft infections has also increased. It is important for physicians who treat aneurysmal disease with endografting to understand the pathophysiology, work-up, and treatment options available. Currently, the mainstay of treatment is prolonged antibiotic therapy, explant of all prosthetic material, and reconstruction of the vasculature with either an in situ or extra-anatomic bypass. However, there is a growing experience of less invasive treatment strategies that can be used in patients who cannot withstand an operation of this magnitude.
Subject(s)
Aortic Aneurysm, Abdominal/surgery , Aortic Aneurysm, Thoracic/surgery , Blood Vessel Prosthesis Implantation/adverse effects , Blood Vessel Prosthesis/adverse effects , Device Removal , Endovascular Procedures/adverse effects , Prosthesis-Related Infections/therapy , Stents/adverse effects , Anti-Bacterial Agents/therapeutic use , Aortography/methods , Blood Vessel Prosthesis Implantation/instrumentation , Endovascular Procedures/instrumentation , Humans , Predictive Value of Tests , Prosthesis Design , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/epidemiology , Prosthesis-Related Infections/microbiology , Prosthesis-Related Infections/surgery , Reoperation , Risk Factors , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
The use of cellular therapy in the treatment of dermal wounds is currently an active area of investigation. Multipotent adult progenitor cells (MAPC) are an attractive choice for cytotherapy because they have a large proliferative potential, the ability to differentiate into different cell types and produce a variety of cytokines and growth factors important to wound healing. Whole bone marrow (BM) was one of the initial attempts to treat impaired wounds. While it has shown some promise, the low frequency of progenitor cell populations in BM and the large number of inflammatory cells make it less attractive. Multipotent mesenchymal stromal cells (MSC) and endothelial progenitor cells are populations of BM-derived progenitor cells that have been isolated and used to treat chronic wounds with some success. Skin-derived MAPC are another heterogeneous population of progenitor cells present in the skin with the potential to differentiate into skin elements and participate in wound healing. All of these progenitor cell populations are potential sources for cytotherapy of wounds. This review focused on the contribution of adult progenitor cell populations to dermal wound healing and their potential for use in cytotherapy.
